Phio Pharmaceuticals is a biotechnology company whose INTASYL™ self-delivering RNA interference technology platform improves the immune cells in killing tumor cells. Co.'s pipeline includes: PH-762, which is designed to reduce the expression of cell death protein 1; PH-894, which is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells; PH-804, which is designed to target TIGIT, a protein that inhibits the activity of Natural Killer cells; PH-109, which is designed to suppress the connective tissue growth factor protein; and an INTASYL compound that is designed to target CTLA-4, a protein that inhibits the ability of T cells to kill tumor cells. We show 22 historical shares outstanding datapoints in our coverage of PHIO's shares outstanding history.
Understanding the changing numbers of PHIO shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like PHIO versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching PHIO by allowing them to research PHIO shares outstanding history
as well as any other stock in our coverage universe. |
Free PHIO Email Alerts:
Video: Shares Outstanding Importance
